Skip to main content
. 2021 Dec 21;2(1):oeab046. doi: 10.1093/ehjopen/oeab046

Graphical Abstract.

Graphical Abstract

Sacubitril/valsartan saved 60% of patients with heart failure with reduced ejection fraction (HFrEF) and without ICD [despite having LVEF  35% and New York Heart Association (NYHA) class II–III at baseline] from implantable cardioverter-defibrillator (ICD) indication after 6 months of therapy.